as 07-26-2024 4:00pm EST
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.
Founded: | N/A | Country: | Australia |
Employees: | N/A | City: | N/A |
Market Cap: | 241.2M | IPO Year: | N/A |
Target Price: | $8.00 | AVG Volume (30 days): | 736.0K |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.26 | EPS Growth: | N/A |
52 Week Low/High: | $1.58 - $3.34 | Next Earning Date: | 08-28-2024 |
Revenue: | $4,576,733 | Revenue Growth: | 3.68% |
Revenue Growth (this year): | -22.27% | Revenue Growth (next year): | 320.36% |
IMMP Breaking Stock News: Dive into IMMP Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
MT Newswires
10 days ago
GlobeNewswire
10 days ago
Zacks
12 days ago
MT Newswires
14 days ago
MT Newswires
14 days ago
MT Newswires
15 days ago
GlobeNewswire
15 days ago
The information presented on this page, "IMMP Immutep Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.